11 Apr 2022 Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
04 Apr 2022 SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
14 Jan 2022 SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity Voraxaze® is now authorized for marketing in all members states of the European Union.
